Skip to content

Advertisement

  • Poster presentation
  • Open Access

Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 3 and
  • 5
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P148

https://doi.org/10.1186/2051-1426-3-S2-P148

  • Published:

Keywords

  • Squamous Cell Carcinoma
  • Esophageal Cancer
  • Thyroid Cancer
  • Dose Level
  • Advanced Cancer

Alpha-tocopheryloxyacetic acid (α-TEA) is a pro-apoptotic agent that demonstrates in vivo anti-tumor activity in pre-clinical models in a T cell-dependent fashion. In IND-enabling studies, orally administered α-TEA lysine salt demonstrated a safety profile in mice and dogs providing rationale for initiating a Phase I clinical trial of α-TEA in patients with advanced cancer (NCT02192346). α-TEA lysine salt was administered to patients in gelatin capsules daily for 28 days. The main clinical objectives of the trial are to characterize α-TEA related toxicity, and determine the maximum tolerated dose, and pharmacokinetics of a-TEA in humans. Secondary objectives are to characterize the phenotype of T-cell subsets in the peripheral blood by flow cytometry. The diagnoses of patients in the ongoing trial include renal cancer, esophageal cancer, thyroid cancer, duodenal cancer, squamous cell oropharyngeal cancer and advanced squamous cell carcinoma of the head and neck. Six patients have been treated at the 2.4mg/kg dose level, and five patients at the 4.8mg/kg dose level. Two patients had atrial fibrillation possibly associated with α-TEA at the 4.8 mg/kg dose level. Grade 2/3 toxicities (24 hour diarrhea) were observed in Subject 1 that in retrospect was not α-TEA related. Subject 3 had grade 4 elevations of hepatocellular enzymes on day 28 from disease progression and grade 3 transient lymphopenia, possibly related to α-TEA. Three patients have stable disease, one lasting 5 months and another lasting 2+ months, which is ongoing. Of interest is that the two patients with stable disease demonstrated an expansion of the CD8+ T cell subset and another patient demonstrated increased CD8 effector memory and substantial increase in expression of the activation markers, CD38 and HLA-DR at day 8 post-treatment. The trial is still accruing patients and the pharmacokinetics, pharmacodynamics, and identification and characterization of α-TEA metabolites in human plasma are ongoing.

Trial registration

ClinicalTrials.gov identifier NCT02192346.

Declarations

Acknowledgments

The study was supported by funds from The Safeway Foundation, Providence Portland Medical Center Foundation and The Heath Foundation.

Authors’ Affiliations

(1)
Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
(2)
Sidra Medical and Research Center, Doha, Qatar
(3)
Providence Portland Medical Center, Portland, OR, USA
(4)
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland, OR, USA
(5)
Earle A. Chiles Research Institute, Portland, OR, USA

Copyright

© Curti et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement